During my nearly decade long trading career, one sector I have always shied away from is Biotechnology (IBB). Volatility is rampant, things can turn on a dime, and the losers are not just losers, but catastrophes. While this doesn't mean I refuse to invest in biotech names, I typically need to find good technical and fundamental reasons to do so. The Great Biotech Wreck of 2015 has made me even more apprehensive to foray into this sector, but I've decided to bite my tongue as a certain name has caught my attention. Not only does Celgene (CELG) boast beefy levels of earnings growth, it's also emerging from a base that's nearly two years in the making. The stock finally looks ready to put this trading range in its rear-view mirror, and it's for this reason I've gone long.
Celgene: Gearing Up For New Highs
7/26/17
Stories you Need to Know
- David Nevins Interviews Dr. Matthew Frieman, Associate Professor, University of Maryland School of Medicine
- Amneal Reports Fourth Quarter and Full Year 2020 Financial Results
- Insmed Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
- Provention Bio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
- Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operational Results
- Pacira BioSciences Reports Full-Year and Fourth Quarter 2020 Financial Results
- MTBC Reports Record Full Year 2020 Results
- Aclaris Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update
- Merck to Acquire Pandion Therapeutics
- Madrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and Highlights


